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Abstract The purpose of the study was to explore associ-
ations between neurocognitive function and chronic kidney
disease (CKD)-related clinical characteristics. Twenty-nine
children, ages 7 to 19 years, with an estimated creatinine
clearance (eCrCl) of 4–89 ml/min per 1.73 m
2 body surface
area were enrolled. Intellectual function (IQ), memory, and
attention were measured and expressed as age-based
standard scores. Clinical data were obtained by physical
examination, laboratory testing, parental questionnaires and
medical chart review. Pearson correlations and standard
Student’s t-tests were used to identify significant (P<0.05)
relationships between targeted clinical variables and neuro-
cognitive scores. Increased CKD severity correlated with
lower IQ (P=0.001) and memory function (P=0.02).
Memory function was lower in children with longer duration
of disease (P=0.03). Similarly, IQ scores were lowest when
kidney disease had started at a younger age (P=0.03) and
with a greater percent of life with CKD (P=0.04). Our
findings provide preliminary evidence that increased dis-
ease severity, longer duration of disease, and younger age
of onset of kidney disease potentially place children with
CKD at increased risk of neurocognitive deficits. Addition-
al investigation is required to better quantify these risk
factors, particularly regarding how much variability is
accounted for by these specific risk factors.
Keywords Pediatrics.Chronicrenalinsufficiency.
Developmental delay.Cognitivedeficits
Introduction
Neurocognitive difficulties have long been observed in the
chronic kidney disease (CKD) population [1]. While
identification and treatment of specific comorbidities of
CKD (e.g., anemia) have yielded improvement in the
overall functioning of this population, reports of neuro-
cognitive deficits in children with CKD continue to appear.
These neurocognitive deficits undoubtedly will have sig-
nificant lifelong implications for the CKD population as
they move into adulthood. A recent review by Groothoff [2]
examined the long-term outcomes of children diagnosed
with CKD and identified persistent difficulties with a
limited knowledge base, memory, and concentration into
adulthood, as well as lower educational attainment. A better
understanding of potential risk factors for cognitive
impairment and decline in the pediatric CKD population
could allow for earlier intervention and, possibly, less
morbidity, particularly for certain cognitive deficiencies.
Studies aimed at investigating neurocognitive impair-
ment in children with CKD have identified a wide range of
delays in motor and cognitive development. Measures of
general intelligence, memory and attention have been used
most frequently to look at cognitive function in the
pediatric CKD population. Most studies have demonstrated
lower IQ scores among children with end stage renal
disease (ESRD) than in unaffected siblings [3] or the
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transplantation performances are compared [6]. Memory
deficits also have been identified in children with mild
CKD as well as ESRD [7]. Fennell et al. [7] also reported in
this same study that there was no significant decline in
measures of attention among these children; however,
improved attention performance has been demonstrated in
children with ESRD after transplantation [6]. Observations
of hyperactivity at school also have been noted in 50% of a
study population assessing cognitive outcomes following
dialysis during infancy [4]. The measures of cognitive
performance in each of these studies varied widely but,
when viewed collectively, suggest that children with CKD
are vulnerable to cognitive deficiencies in IQ, memory and
attention.
One thing to note, however, is that most studies to date
have focused primarily on children with ESRD, leaving
unanswered whether children with mild to moderate CKD
also suffer this same vulnerability. Cognitive deficiencies in
children with CKD could arise through a gradual process,
proportional to the level of kidney dysfunction, or may
develop once a filtration threshold has been passed. It
seems logical that the severity of CKD might be propor-
tional to the degree of cognitive impairment, but the data
are not yet available to support this. The stage of neurologic
development at the time of disease onset or the cumulative
time children spend with CKD may also impact on the
degree or type of cognitive impairment experienced. To our
knowledge, no published study has yet focused specifically
on isolating risk factors to identify which children with
CKD are most at risk for cognitive decline. The primary
goal of this study was to explore associations between
clinical aspects describing CKD and selected neurocogni-
tive test scores in a sample of children and adolescents with
CKD. In addition, this study should provide the foundation
for identifying specific clinical risk factors for subsequent
neurodevelopmental dysfunction.
Methods
Participants
Study participants were recruited from a university-based
pediatric nephrology practice. The participants included
children between 7 and 19 years of age, with an estimated
creatinine clearance (eCrCl) by Schwartz formula [8]o f
less than 90 ml/min per 1.73 m
2 body surface area for at
least 3 months duration. Renal transplant recipients and
children with profound developmental delays were exclud-
ed. Following parental consent and patient assent, 29
children meeting these criteria underwent neurocognitive
testing at a single point in time. A standardized physical
examination and laboratory sample collection were also
performed within 2 weeks of cognitive testing. A question-
naire providing demographic and historic information was
completed by a parent or legal guardian. The study was
reviewed and approved by the University of North Carolina
Institutional Review Board.
Included among the study sample were 17 children with
obstructive uropathy or structural congenital renal anomalies,
seven with glomerulonephritis, one with calcineurin inhibitor
toxicity, one who had sustained ischemic injury, one with
renal insufficiency of undetermined etiology, one child with
Alport’s syndrome, and one with cystinosis. Participants
were evenly divided with respect to gender and disease
severity. Approximately half the study sample had mild to
moderate CKD with eCrCl ranging from 31–89 ml/min per
1.73 m
2 body surface area. Kidney disease onset was
documented from birth in 59%. The majority (59%) were
hypertensive, and, among these children, 70% were on
antihypertensive therapy, and 65% had measured blood
pressure above the 95th percentile at the time of examina-
tion. The mean hemoglobin level was 12.7 mg/dl, with only
three (10%) below 11 mg/dl, with values of 10.8 mg/dl,
10.7 mg/dl and 10.1 mg/dl. The general characteristics of our
study sample are described in Table 1. All the participants
attended school in a regular classroom setting, and two
reported having an individualized education plan (IEP) at the
time of participation.
Neurocognitive instruments
All participants completed a battery of intellectual, atten-
tion, and memory tasks as part of a larger neuropsycholog-
ical evaluation. To gain an estimate of overall intellectual
functioning, we administered the Wechsler Abbreviated
Scale of Intelligence [9]. The Gordon Diagnostic System
Table 1 Demographic characteristics and medical variables of the
study sample (PD peritoneal dialysis, HD hemodialysis)
Study sample characteristics Number
(n=29)
a
Range
Age (years) 12.5 (3.2) 7–19
Male (%) 52
Caucasian (%) 52
eCrCl (ml/min per 1.73 m
2 body surface area) 32 (29) 4–89
ESRD (13 PD, 1 HD) (%) 48
Age at disease onset (years) 4.4 (5.9) 0–16
Duration of CKD (years) 6.7 (4.7) 0.2–15
Percent of life with CKD 69 (39) 1–100
Hypertensive (%) 59
Hemoglobin (mg/dl) 12.7 (1.5) 10–17
aMean (standard deviation) or percent
566 Pediatr Nephrol (2007) 22:565–572[10], a computerized continuous performance test, was also
administered to gain an estimate of attention functioning.
Within the memory domain, the Wide Range Assessment of
Memory and Learning [11] was employed to assess short-
term memory across verbal and visual domains. Age-based
standard scores (mean=100, standard deviation=15) were
generated for variables from each of these tasks. In all
instances, higher scores represented higher function for
each cognitive test result. All tasks were administered by
trained examiners who were supervised by a child
neuropsychologist.
The Wechsler Abbreviated Scales of Intelligence (WASI)
is built on the well-known Wechsler measures of global
intellectual functioning [9]. It was designed for ages 6 years
through adulthood, and employs a fluid-crystal model of
intelligence. Four subtests comprise the WASI and include
vocabulary, block design, similarities, and matrix reason-
ing. All four subtests were administered to gain a brief full
scale IQ score.
The Gordon Diagnostic System (GDS) is a computerized
continuous performance test that measures various aspects
of visual attention [10]. For this study, the vigilance task
was administered, which requires the individual to respond
to specific visual stimuli (e.g., the number 1 followed by
the number 9) from a series of numbers presented at a rate
of approximately one per second. This task yields standard
scores for the number correct, correct variability, commis-
sions, and commission variability. For this study, the total
correct standard score was employed.
The Wide Range Assessment of Memory and Learning
(WRAML) is a comprehensive memory battery of tests
[11]. It includes nine different subtests that measure short-
term verbal memory (story memory, sentence memory,
number/letter), short-term visual memory (picture memory,
design memory, finger windows), and new learning
capabilities (sound symbol, visual learning, verbal learn-
ing). A general memory index is also computed from the
nine subtests. Normative data are available for ages 6
through 18 years. The WRAML was administered and
scored according to standardized procedures, with the
general memory index being employed for this study.
Clinical measures
Disease severity, age of onset, and duration of renal disease,
coded as time in years and as percent of life with CKD, as
well as the presence of anemia or hypertension were
explored as potential risk factors of interest, given their
association with detrimental cognitive outcomes in the
CKD literature. Clinical data were collected through
physical examinations and laboratory tests performed
within 2 weeks of cognitive testing. Age of disease onset,
as well as duration and percent of life with CKD, were
determined through record reviews and were based on the
date of primary disease diagnosis.
The Schwartz formula [8], using creatinine and height
measurements, was used to estimate the eCrCl for non-
dialysis patients. Creatinine clearance and urea kinetics were
calculated for peritoneal dialysis patients from a 24 h fluid
collection. All but three of the peritoneal dialysis patients
exceeded Kidney Disease Outcomes Quality Initiative
(K/DOQI) guidelines for maintaining a Kt/V of at least
2.0, and those not achieving this level ranged from 1.8
to 1.9 [12]. For our continuous analysis, we represented the
eCrCl from the 24 h fluid collection from dialysis patients
(incorporating residual renal function for the six dialysis
patients who still produced urine) on a continuum with the
eCrCl from the Schwartz formula that had been calculated
for CKD patients. The one hemodialysis participant had a
Kt/V of 1.34 and received dialysis four times a week. For
analysis, we imputed this participant’s eCrCl, designating the
mean creatinine clearance value from anuric peritoneal
dialysis participants. For the dichotomous analysis, “mild to
moderate” disease was categorized as an eCrCl of 30 to
89 ml/min per 1.73 m
2 body surface area, representing those
patients with stage 2 or 3 CKD as defined by K/DOQI
guidelines [12]. Those with an eCrCl of less than 30 ml/min
per 1.73 m
2 or those on dialysis, consistent with stage 4 or 5
CKD, were categorized as “severe CKD/ESRD”.
Anemia was defined as a hemoglobin level of less than
11 mg/dl, reflecting the normative ranges of hemoglobin for
children aged 9 years and above and the K/DOQI guide-
lines that specify a target hemoglobin level of 11–12 mg/dl
in CKD [13]. Hypertension was defined as either the
regular use of antihypertensive medications or the presence
of a blood pressure greater than the 95th percentile for age,
height, and gender [14].
Data analysis
Initial summary statistical analysis was used to describe the
total study sample. This included both descriptive analysis
and graphical examination of all relevant variables. To
address the primary research question for this study, we
used bivariate analysis comparing neurocognitive scores
and the clinical characteristics of the study sample, using
Pearson’s correlations for all continuous variables. Trend
analysis based on linear regression was also used when
continuous variables were compared graphically. For those
variables that, by definition, were dichotomous (e.g.,
hypertension), Student’s t-tests were used to compare the
mean neurocognitive scores between categories. For those
clinical variables for which an argument could be made
either to express continuously or to dichotomize on the
basis of a normal range (e.g., hemoglobin), both correla-
tions and t-tests were used.
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An initial inspection of the neurocognitive test scores
showed that the sample of children and adolescents with
CKD was mildly variable, with most of the participants
falling within the low average to average range on most
tasks. For the full study sample, the mean IQ score was 91
(range 61 to 117, SD16), and the mean memory score was
88 (range 65 to 128, SD16), both falling within the low
average to average range when compared with normative
expectations. The mean attention score of 96 fell well
within the average range but did show much more
variability (range 37 to 120, SD23).
Disease severity
Disease severity, represented by the eCrCl, yielded the
strongest relationship with both IQ (r=0.57, P=0.001) and
memory (r=0.45, P=0.02), demonstrating that higher
eCrCl correlated with higher scores in these cognitive
domains. Figures 1 and 2 illustrate the linear trend in the
relationship between the continuous representation of
disease severity and both IQ and memory scores. The
correlation between attention and eCrCl was not significant.
Additionally, lower IQ measures among severe CKD/ESRD
participants in our study were evident when compared
dichotomously with those with mild to moderate CKD (P=
0.0008), and the same relationships held for memory scores
(P=0.009) and attention scores (P=0.012), despite the fact
that attention was not linearly associated with eCrCl. Figure 3
illustrates the mean cognitive scores for categories of
disease severity. While a downward trend with increasing
severity is observed across all cognitive domains, statistical
analysis confined to only the 15 non-dialysis patients
yielded similar but less robust correlations among all areas
of cognition, with IQ being the strongest (r=0.46, P=0.08).
Age at disease onset and CKD duration
Increased CKD duration in years was associated with lower
memory scores (r=−0.40, P=0.03). Age at disease onset
did not correlate significantly with IQ, memory, or attention
scores in our original analysis. However, it was noted that
many participants in our study sample had presented with
already severe disease, making the date of disease diagnosis
less reflective of the actual age at which reduced renal
function began. In a secondary exploratory analysis, we
repeated our analysis using only those subjects (n=10) for
whom we had a clearly documented date on which the
eCrCl dropped below 90 ml/min per 1.73 m
2. Among these
patients were six with obstructive uropathy or structural
congenital renal anomalies, three with glomerulonephritis,
and one with cystinosis. In this secondary analysis we
observed that the direction of prior relationships was
preserved, with a stronger relationship between IQ and
both age at disease onset (r=0.69, P=0.03) and percent of
life with CKD (r=−0.66, P=0.04). This may indicate that
younger age at onset of CKD and longer percent of life
with CKD correlate with lower IQ scores.
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Table 2 summarizes the results of our analysis of
hypertension and anemia. The dichotomous separation of
these two variables did not produce significant group
differences. These findings suggest that the presence of
anemia or hypertension at the time of testing did not
correlate with differences in neurocognitive test results
between study participants with or without these clinical
features. In a secondary analysis we also explored designa-
tion of hypertension, defined initially as either the use of
antihypertensive medications or the presence of hyperten-
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of each criterion separately, and we found no differences.
Additional examination of anemia revealed that only three
patients had a hemoglobin level below the anemia
definition of < 11 mg/dl, with values of 10.8 mg/dl,
10.7 mg/dl and 10.1 mg/dl. Consequently, we were unable
to assess anemic patients across a wide range of hemoglo-
bin (Hb) values. Within our sample of hemoglobin ranging
between 10.1 mg/dl and 17.0 mg/dl, no association between
our cognitive domains and hemoglobin was observed.
The use of a contemporary blood pressure or hemoglo-
bin value to represent the hypertension or anemia status of
our participants evaluated the potential effect of these
factors on their cognitive performance on the day of testing.
Day-to-day changes in blood pressure could cause changes
in cognitive function. Another approach is to use time-
averaged hemoglobin and blood pressure values as markers
of long-term strain on cognitive skills. Therefore, we also
did a retrospective chart review of all blood pressure and
hemoglobin values recorded in the 6 months prior to the
study visit and generated a mean value for each of these
two variables. On the basis of these time-averaged values,
we repeated our analysis. In the blood pressure range
represented, hypertension remained unrelated to any of the
cognitive variables. Hemoglobin levels, however, demon-
strated a subtle correlation with memory performance in the
continuous analysis (r=0.41, P=0.03). Dichotomous anal-
ysis of anemia yielded a significant difference in cognitive
scores only when defined as a time-averaged hemoglobin
level less than 10.5 mg/dl (mean memory score of 67
among anemic patients versus 91 among non-anemic
participants, P=0.01). However, this must be interpreted
with caution, since only three participants fulfilled this
criterion for anemia.
We should also acknowledge that there is a high degree
of correlation among the results of the individual cognitive
domains tested. Among the children included in our study,
12 (41%) had no cognitive scores greater than one standard
deviation below the normative mean of 100, eight (28%)
deviated in this fashion in a single cognitive domain, three
(10%) did so in two areas, and six (21%) did so in all three
areas. The level of overlap is, in part, likely due to the
nature of cognitive testing, whereby testing in one area is,
to some degree, dependent upon function in another area.
The fact that there is not complete overlap, however,
indicates that cognitive testing can distinguish among these
deficits with some level of specificity.
Discussion
Neurocognitive deficits among children with ESRD have
been demonstrated in the literature, with some suggestion
that key clinical variables can be associated with the level
and, perhaps, the pattern of these deficits. The primary
purpose of this study was to examine the relationship
between targeted clinical variables, based on the available
literature, and selected neurocognitive functions as defined
by IQ, memory, and attention. Further, the current study
examines these relationships across the full spectrum of
CKD, including the mild to moderate stages of CKD. While
it is recognized that some of the etiologies leading to CKD
in our patients, namely cystinosis, calcineurin inhibitor
toxicity, and ischemic injury, could potentially be indepen-
dently associated with some level of cognitive dysfunction,
in all three cases the children did not demonstrate evidence
of other neurologic signs that would indicate central
nervous system damage from their underlying disorders.
Additionally, these children are representative of a typical
pediatric CKD population, and any contribution from the
presence of their comorbid conditions would not compro-
mise the validity of our findings.
In the current study, several key findings were evident.
First, disease severity significantly correlated with IQ and
memory, while duration of disease significantly correlated
with memory in the expected direction. Age at onset and
percent of life with CKD did not initially correlate with any
of the neurocognitive indices. When the age at onset and
percent of life with the disease were examined in a
secondary analysis restricted to a group of participants with
more precisely defined onset of true decreased renal
function, there was a clear trend that suggested that the
younger the age at onset and the greater the percent of life
with CKD, the lower the IQ score. The finding that younger
age at renal insufficiency onset is significantly related to
lower IQ complements previous observations in two prior
studies of children with ESRD [3, 15]. Lawry et al. [15]
found that among 24 children, including both dialysis and
transplant patients, younger age at ESRD onset correlated
with lower IQ scores. Brouhard et al. [3] also found that
younger age at renal diagnosis was associated with lower
achievement scores, although not specifically with lower IQ
scores.
Table 2 Relationships between hypertension, anemia and cognitive
measures
Number (n=29) IQ
a General memory
a Attention
a
Total cohort 91 (16) 88 (16) 96 (23)
Non-hypertensive 90 (18) 87 (16) 89 (24)
Hypertensive 92 (15) 89 (17) 100 (21)
Non-anemic 91 (16) 89 (16) 98 (22)
Anemic (<11 mg/dl) 92 (17) 81 (23) 76 (20)
aFor each represented test among the normal population, the mean is
100 with a standard deviation of 15. No significant differences on
Student’s t-tests for hypertension or anemia.
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memory scores among the ESRD subset of our study
sample, as can be observed in Figs. 1 and 2. This might
reflect the presence of other clinical variables, such as
duration on dialysis, dialysis adequacy, or presence of
residual renal function, which could also influence cogni-
tive performance. A similar wide range of results among
children with ESRD has been observed in other study
samples, such as that of Brouhard et al. [3], in which
children with renal disease had scores that included some in
the average range but still had mean IQ and achievement
scores significantly lower than their healthy sibling con-
trols. These findings support the hypothesis that disease
severity plays a strong role in predicting neurocognitive
vulnerability, yet also suggest that there might be additional
contributing variables characterizing end stage disease that
warrant further investigation. In an effort to explore this
issue further, the sub-analysis confined to the relationship
between disease severity and cognitive outcomes in the
non-dialysis participants demonstrated a more subtle down-
ward trend of scores across all cognitive domains that did
not reach statistical significance. This was likely, in part,
due to the reduction in power resulting from our limiting
the analysis to only 15 participants. It also might suggest
that therapy with dialysis itself contributes to cognitive
dysfunction.
The literature has been more ambiguous with regard to
attention, and our findings did not demonstrate a significant
deficit in attention. Our sample did, however, demonstrate
significantly more variation in the attention measure among
children with CKD than one would anticipate in the general
population, as exhibited by the large standard deviation in
our study sample. This suggests the possibility that there
may be a subset of children with CKD who are more
vulnerable to attention-related problems. More extensive
exploration of the various components of attention may be
required to explore this observation further.
Hypertension, as a single measure or time-averaged, was
not associated with the neurocognitive outcomes evaluated.
Hypertension in the general pediatric population has been
correlated with decreased performance in tasks requiring
memory, attention, and concentration [16]. Using school-
aged children from a population-based US survey who were
diagnosed with hypertension on the basis of systolic or
diastolic blood pressure above the 90th percentile for age,
height and gender, Lande et al. [16] showed that hyperten-
sion was significantly associated with lower neurocognitive
scores representative of short-term memory, attention and
concentration problems. In our study sample of children
with CKD, the majority of our participants were on
antihypertensive therapy, so any existing hypertension in
our study sample was at least partially treated, thus
significantly restricting the range of variance available for
correlation analysis. Furthermore, some antihypertensive
therapies, for instance clonidine, have the potential to cause
sedating effects in children but can actually help concen-
tration in other children. The effects of medications on just
a few children could appear amplified in our small study
sample, and, thus, a true relationship could be obscured.
The hemoglobin level at the time of testing did not
predict cognitive function. Time-averaged hemoglobin
concentrations less than 10.5 mg/dl were associated with
lower memory performance. It has also been well estab-
lished that anemia is associated with decreased cognitive
function in adult patients with renal disease [17, 18].
Stivelman’s review on the topic highlights several studies
investigating the use of erythropoietin in uremic adult
patients. Increasing hematocrit was associated with im-
proved neurocognitive measures [17]. For example, Marsh
et al. [18] used erythropoietin in 24 adult hemodialysis
patients to improve their average hematocrit from 23% to
36%, resulting in significantly improved neuropsychologi-
cal test scores reflecting memory, learning and attention. In
our study sample of children with CKD, only three children
had a low hemoglobin level, and these were between
10.1 mg/dl and 10.8 mg/dl. The mean scores for memory
and attention among those three children were 8 points and
22 points lower, respectively, than those for non-anemic
children, suggesting that there could be a relationship that
would require a larger sample size to identify. In the normal
or near-normal range, detrimental effects of lower hemo-
globin levels are likely more subtle and, thus, less likely to
be captured in analysis of a small sample. Our time-
averaged hemoglobin analysis supported this as well.
This is the first study to date that focuses specifically on
identifying potential risk factors for neurocognitive decline
in children and adolescents with CKD. Its value is further
enhanced by the inclusion of children with mild to
moderate CKD, thus extending findings to a wider range
of pediatric CKD patients. Increased disease severity,
duration of CKD, and younger age at CKD onset were
identified as potential risk factors for the targeted neuro-
psychological functions of IQ and memory. Our results
further suggest a significant linear relationship with disease
severity, with IQ scores continuously declining as disease
severity worsens. Not only does this finding argue against a
threshold effect, it implicates disease severity as an
important risk factor for neuropsychological dysfunction.
These findings also suggest the possible utility of these
variables in a cumulative risk model to predict neuro-
cognitive dysfunction in CKD and lay the foundation for
exploration of such a model. Finally, these findings
emphasize the importance of conducting further research
in neurocognitive development among children with CKD.
This includes research both to more clearly predict which
children with CKD are most vulnerable to neuropsycho-
Pediatr Nephrol (2007) 22:565–572 571logical dysfunction and to identify specific correlates of this
dysfunction. While there have been great strides in
improving quality and length of life among children with
CKD, a better understanding of those processes that
interfere with normal neurodevelopment is a critical
element of providing optimal care to these children.
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